Abstract
Ulcerative colitis is a chronic, idiopathic inflammatory disease of the colon characterized by periods of exacerbation and remission. Medical treatment aims to provide rapid effective relief from symptoms, modify the disease process and improve quality of life. Many oral preparations use multiple daily dosing regimens which can be inconvenient and affect treatment adherence leading to increased morbidity and risk of symptomatic relapse. This article examines the issues surrounding the use of mesalazine in ulcerative colitis, focusing on Mezavant XL (MMX mesalazine), a once-daily dosing formulation with patented multi-matrix system. The reader will gain an understanding of the pharmacology of the drug, evidence base for its use and implications for prescribing practice.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
